DUBLIN, April 4, 2019 /PRNewswire/ — The “Influenza Vaccine Market – Forecasts from 2019 to 2024” report has been added to ResearchAndMarkets.com’s offering.
The global influenza vaccine market is projected to grow at a CAGR of 6.37% to reach US$7.547 billion by 2024, from US$5.209 billion in 2018.
Due to the constant changing of circulating influenza viruses, influenza vaccines strains are changed annually (for both the Northern Hemisphere and the Southern Hemisphere) to more closely match currently circulating virus strains (source: WHO). Hence the rising R&D expenditure and advancements in vaccine technology are driving the growth of the global influenza vaccine market in the forecast period. Furthermore, growing immunization for the prevention of influenza virus infection will emanate the market growth in the coming years and beyond.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research.
Major industry players profiled as part of the report are Seqirus, GlaxoSmithKline plc., Sanofi Pasteur SA., Novavax, Inc., Emergent BioSolutions Inc. among others.
Key Topics Covered:
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.6. Base and Forecast Years Timeline
2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
3. Executive Summary
4. Market Dynamics
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.6. Life Cycle Analysis – Regional Snapshot
4.7. Market Attractiveness
5. Global Influenza Vaccine Market by Vaccine Technology
6. Global Influenza Vaccine Market by End-User
7. Global Influenza Vaccine Market by Geography
7.1. North America
7.2. South America
7.3.3. United Kingdom
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.5. Asia Pacific
7.5.3. South Korea
8. Competitive Intelligence
8.1. Competition and Offerings Analysis of Key Vendors
8.2. Recent Investment and Deals
8.3. Strategies of Key Players
9. Company Profiles
9.2. Glaxosmithkline Plc.
9.3. Sanofi Pasteur Sa.
9.4. Novavax, Inc.
9.5. Emergent Biosolutions Inc.
9.6. Csl Limited
9.7. Pfizer Limited
9.8. Gamma Vaccines Pty Ltd
9.10. F. Hoffmann-La Roche Ltd
For more information about this report visit https://www.researchandmarkets.com/research/hkhc29/global_influenza?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets